Amgen will continue to advance half of the combo, PRMT5 inhibitor AMG 193, for which it is running a mid-stage trial in ...

Diagnosed with stage 3B lung cancer in 2018, I joined a support group where I met Jim and Melanie, and learned about Jim's ...

Researchers from the Francis Crick Institute have found that some particularly aggressive lung cancer cells can develop their ...

The following is a summary of “Transcriptional regulatory network analysis identifies GRN as a key regulator bridging chemotherapy and immunotherapy response in small cell lung cancer,” published in ...

Upon Opdualag’s approval in 2022 as a first-in-class cancer immunotherapy, Bristol Myers Squibb was anxious to explore its potential in a variety of indications. | Bristol Myers Squibb is striking out ...

Bristol Myers Squibb said it is disappointed with the outcome of a study that examined whether one of its drugs could be used to treat a certain type of skin cancer. The drug, Opdualag, didn't meet ...

Recursion is advancing REC-617, a promising reversible, non-covalent CDK7 inhibitor, showing potential in treating advanced solid tumors with positive interim phase 1 data. Read more here.

Patients Achieved Remission Within 30 Days in Cohort 1 of the Mipletamig RAINIER Dose Optimization Trial for Frontline AML Patients, Trial Enrollment ContinuesPromising Data, including a 59% Stable ...

Builds on Global Intellectual Property Portfolio to Protect DNAbilize® PlatformHOUSTON, Feb. 13, 2025 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ:BPTH), a biotechnology company leveraging its ...

Nuvation has a best-in-class lung cancer drug that could be approved in the US in June. Read why I'm bullish on the stock ...

EVENTS DURING THE FOURTH QUARTEREuropean Patent Office granted Active Biotech's patent application for eye drop formulation of laquinimod (October 23)Active Biotech's clinical trial of tasquinimod in ...